Journal of Pediatrics Review

Published by: Kowsar

Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review

Ali Abbaskhanian 1 , * and Soheila Shahmohammadi 2
Authors Information
1 Associate Professor, Department of Pediatric Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
2 CRNA, Research Fellow, Infectious Disease Research Center with Focus on Nosocomial Infection, Bouali Sina Hospital, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Journal of Pediatrics Review: July 2016, 4 (2); e6276
  • Published Online: June 26, 2016
  • Article Type: Review Article
  • Received: April 9, 2016
  • Revised: May 31, 2016
  • Accepted: June 1, 2016
  • DOI: 10.17795/jpr-6276

To Cite: Abbaskhanian A, Shahmohammadi S. Add-on Levetiracetam in Children With Refractory Epilepsy: A Systematic Review, J Pediatr Rev. 2016 ;4(2):e6276. doi: 10.17795/jpr-6276.

Abstract
Copyright: Copyright © 2016, Journal of Pediatrics Review. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
References
  • 1. Weijenberg A, Brouwer OF, Callenbach PM. Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review. CNS Drugs. 2015; 29(5): 371-82[DOI][PubMed]
  • 2. Opp J, Tuxhorn I, May T, Kluger G, Wiemer-Kruel A, Kurlemann G, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure. 2005; 14(7): 476-84[DOI][PubMed]
  • 3. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004; 101(26): 9861-6[DOI][PubMed]
  • 4. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001; 306(1-2): 5-8[PubMed]
  • 5. Vigevano F. Levetiracetam in pediatrics. J Child Neurol. 2005; 20(2): 87-93[PubMed]
  • 6. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001; 42(12): 1574-9[PubMed]
  • 7. Lyseng-Williamson KA. Levetiracetam. Drugs. 2011; 71(4): 489-514
  • 8. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999; 34(2-3): 161-8[PubMed]
  • 9. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996; 31(1): 29-46[DOI][PubMed]
  • 10. Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol. 2008; 12(4): 321-7[DOI][PubMed]
  • 11. Grosso S, Franzoni E, Coppola G, Iannetti P, Verrotti A, Cordelli DM, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure. 2005; 14(4): 248-53[DOI][PubMed]
  • 12. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure. 2005; 14(1): 66-71[DOI][PubMed]
  • 13. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006; 66(11): 1654-60[DOI][PubMed]
  • 14. Peake D, Mordekar S, Gosalakkal J, Mukhtyar B, Buch S, Crane J, et al. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure. 2007; 16(2): 185-9[DOI][PubMed]
  • 15. Grosso S, Cordelli DM, Franzoni E, Coppola G, Capovilla G, Zamponi N, et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure. 2007; 16(4): 345-50[DOI][PubMed]
  • 16. Kanemura H, Sano F, Tando T, Sugita K, Aihara M. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. Brain Dev. 2013; 35(5): 386-91[DOI][PubMed]
  • 17. Stuelpnagel C, Holthausen H, Kluger G. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy. Eur J Paediatr Neurol. 2007; 11(6): 341-5[DOI][PubMed]
  • 18. Pina-Garza JE, Nordli DJ, Rating D, Yang H, Schiemann-Delgado J, Duncan B, et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009; 50(5): 1141-9[DOI][PubMed]
  • 19. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia. 2000; 41(10): 1276-83[PubMed]
  • 20. Levetiracetam in childhood treatment-resistant epilepsy. Epilepsia. : 144-5
  • 21. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol. 2002; 17(6): 413-5[PubMed]
  • 22. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure. 2004; 13(3): 142-5[DOI][PubMed]
  • 23. Mandelbaum DE, Bunch M, Kugler SL, Venkatasubramanian A, Wollack JB. Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use. J Child Neurol. 2005; 20(7): 590-4[PubMed]
  • 24. Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001; 56(12): 1772-4[PubMed]
  • 25. Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002; 43(5): 518-24[PubMed]
  • 26. Glauser TA, Dulac O. Preliminary efficacy of levetiracetam in children. Epileptic Disord. 2003; 5 Suppl 1-50[PubMed]
  • 27. Herranz JL. [Levetiracetam in children and adolescents with epilepsy]. Rev Neurol. 2003; 37(6): 558-60[PubMed]
  • 28. Mohanraj R, Parker PG, Stephen LJ, Brodie MJ. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure. 2005; 14(1): 23-7[DOI][PubMed]
  • 29. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000; 55(2): 236-42[PubMed]
  • 30. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia. 2000; 41(9): 1179-86[PubMed]
  • 31. Veendrick-Meekes M, Renier WO, Oei LT, Lambrechts D. Levetiracetam therapy in children and adolescents with intractable epilepsy. Epilepsia . 2002; 43: 37
  • 32. Nakken KO, Eriksson AS, Lossius R, Johannessen SI. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure. 2003; 12(1): 42-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader